Jamie S. Pak

422 total citations
25 papers, 325 citations indexed

About

Jamie S. Pak is a scholar working on Surgery, Urology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jamie S. Pak has authored 25 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 7 papers in Urology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jamie S. Pak's work include Bladder and Urothelial Cancer Treatments (14 papers), Urinary and Genital Oncology Studies (13 papers) and Urological Disorders and Treatments (6 papers). Jamie S. Pak is often cited by papers focused on Bladder and Urothelial Cancer Treatments (14 papers), Urinary and Genital Oncology Studies (13 papers) and Urological Disorders and Treatments (6 papers). Jamie S. Pak collaborates with scholars based in United States, Iran and France. Jamie S. Pak's co-authors include James M. McKiernan, G. Joel DeCastro, Arindam RoyChoudhury, Mitchell C. Benson, Danny Lascano, Julia B. Finkelstein, Kimberly L. Cooper, Trinity J. Bivalacqua, Gina M. Badalato and E.W. Hagen and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Urology.

In The Last Decade

Jamie S. Pak

23 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jamie S. Pak United States 10 178 70 66 64 64 25 325
Ling Y. Chen United States 10 189 1.1× 8 0.1× 106 1.6× 70 1.1× 63 1.0× 14 364
Sarah A. Vogler United States 12 252 1.4× 8 0.1× 66 1.0× 20 0.3× 89 1.4× 21 370
Carlos Riveros United States 8 44 0.2× 6 0.1× 46 0.7× 15 0.2× 25 0.4× 41 226
Michael Valente United States 12 361 2.0× 7 0.1× 104 1.6× 5 0.1× 237 3.7× 89 559
Ahmed Hammad United Kingdom 8 138 0.8× 37 0.5× 28 0.4× 28 0.4× 55 0.9× 25 247
Danielle A. Bischof United States 11 210 1.2× 5 0.1× 150 2.3× 6 0.1× 97 1.5× 17 409
David Beddy Ireland 10 293 1.6× 32 0.5× 63 1.0× 7 0.1× 183 2.9× 19 516
Sailaja Pisipati United States 9 173 1.0× 4 0.1× 74 1.1× 31 0.5× 67 1.0× 37 298
Lieke Gietelink Netherlands 10 172 1.0× 13 0.2× 68 1.0× 8 0.1× 205 3.2× 13 298
Jacob C. Hodges United States 7 129 0.7× 43 0.6× 93 1.4× 2 0.0× 126 2.0× 25 260

Countries citing papers authored by Jamie S. Pak

Since Specialization
Citations

This map shows the geographic impact of Jamie S. Pak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie S. Pak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie S. Pak more than expected).

Fields of papers citing papers by Jamie S. Pak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie S. Pak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie S. Pak. The network helps show where Jamie S. Pak may publish in the future.

Co-authorship network of co-authors of Jamie S. Pak

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie S. Pak. A scholar is included among the top collaborators of Jamie S. Pak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie S. Pak. Jamie S. Pak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Christin, John R., Jamie S. Pak, Helena Vila-Reyes, et al.. (2024). MP16-18 COMBINATION REGIMEN OF INTRAVESICAL DOCETAXEL, GEMCITABINE, AND CISPLATIN IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. The Journal of Urology. 211(5S). 1 indexed citations
2.
Pak, Jamie S., et al.. (2021). Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 39(11). 787.e9–787.e15. 10 indexed citations
3.
Pak, Jamie S., et al.. (2020). A Urology Department's Experience at the Epicenter of the COVID-19 Pandemic. Urology. 144. 4–8. 4 indexed citations
4.
Wang, Elizabeth, Jamie S. Pak, Renu K. Virk, et al.. (2020). Bladder Preservation for Patients With Bladder Paragangliomas: Case Series and Review of the Literature. Urology. 143. 194–205. 3 indexed citations
5.
Vila-Reyes, Helena, G. Joel DeCastro, Izak Faiena, et al.. (2020). MP73-09 EFFECTIVENESS OF COMBINATION CISPLATIN-BASED INTRAVESICAL CHEMOTHERAPY FOR BCG-REFRACTORY BLADDER CANCER. The Journal of Urology. 203(Supplement 4).
6.
Pak, Jamie S., Helena Vila-Reyes, Christopher B. Anderson, et al.. (2020). Oncologic outcomes of complete transurethral resection prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.. Journal of Clinical Oncology. 38(15_suppl). e17029–e17029. 1 indexed citations
7.
Asafu‐Adjei, Denise, et al.. (2019). The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity. Canadian Urological Association Journal. 14(10). E520–E526. 4 indexed citations
8.
DeCastro, G. Joel, Christopher B. Anderson, Jamie S. Pak, et al.. (2019). MP43-14 A PHASE 1 TRIAL OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) FOR THE TREATMENT OF NON-MUSCLE INVASIVE BCG UNRESPONSIVE UROTHELIAL CARCINOMA OF THE BLADDER. The Journal of Urology. 201(Supplement 4). 2 indexed citations
9.
Sui, Wilson, et al.. (2017). Gender Differences in the Urology Residency Match—Does It Make a Difference?. Urology. 111. 39–43. 17 indexed citations
10.
Whalen, Michael J., Jamie S. Pak, Danny Lascano, et al.. (2017). Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance. Clinical Genitourinary Cancer. 16(2). e425–e435. 5 indexed citations
11.
12.
Pak, Jamie S., et al.. (2017). Utilization Trends and Short-term Outcomes of Robotic Versus Open Radical Cystectomy for Bladder Cancer. Urology. 103. 117–123. 15 indexed citations
13.
14.
Pak, Jamie S., et al.. (2016). Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy. Journal of Robotic Surgery. 11(2). 223–229. 14 indexed citations
15.
Lascano, Danny, Jamie S. Pak, Max Kates, et al.. (2015). Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools. Urologic Oncology Seminars and Original Investigations. 33(10). 426.e1–426.e12. 90 indexed citations
16.
Pak, Jamie S., et al.. (2015). Male Urethral, Penile, and Incontinence Surgery: Is Resident Exposure Adequate?. Urology. 86(5). 868–872. 7 indexed citations
17.
Pak, Jamie S., Danny Lascano, Julia B. Finkelstein, et al.. (2015). Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation. Urologic Oncology Seminars and Original Investigations. 33(10). 426.e13–426.e19. 22 indexed citations
18.
Whalen, Michael J., Matthew Danzig, Jamie S. Pak, et al.. (2015). Utilization and Perioperative Outcomes of Partial Cystectomy for Urothelial Carcinoma of the Bladder: Lessons from the ACS NSQIP Database. Urology Practice. 2(3). 109–114. 3 indexed citations
19.
Lascano, Danny, Jamie S. Pak, Alexander Small, et al.. (2015). MP14-03 SIMPLIFIED FRAILTY INDEX PREDICTS ADVERSE SURGICAL OUTCOMES AND INCREASED LENGTH OF STAY IN RADICAL PROSTATECTOMY PATIENTS: AN ANALYSIS OF THE ACS-NSQIP DATABASE. The Journal of Urology. 193(4S). 1 indexed citations
20.
McKiernan, James M., Danny Lascano, Jennifer Ahn, et al.. (2015). A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer.. Journal of Clinical Oncology. 33(15_suppl). TPS4576–TPS4576. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ling Y. Chen Breakdown of academic impact, for papers by Sarah A. Vogler Breakdown of academic impact, for papers by Carlos Riveros Breakdown of academic impact, for papers by Michael Valente Breakdown of academic impact, for papers by Ahmed Hammad Breakdown of academic impact, for papers by Danielle A. Bischof Breakdown of academic impact, for papers by David Beddy Breakdown of academic impact, for papers by Sailaja Pisipati Breakdown of academic impact, for papers by Lieke Gietelink Breakdown of academic impact, for papers by Jacob C. Hodges
Rankless by CCL
2026